Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

NCT05112939
View directory record Official record
Conditions
Healthy
Interventions
RPV LA, CAB LA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Withdrawn Phase 2 Interventional

Intranasal Oxytocin and Learning in Autism

NCT02090829
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Syntocinon (synthetic oxytocin), Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 31, 2026, 2:44 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

NCT05289037
View directory record Official record
Conditions
COVID-19
Interventions
AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

NCT02084875
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified-release (MR) formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

NCT00812630
View directory record Official record
Conditions
Blood Pressure
Interventions
MENT or placebo
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Results available

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

NCT01318902
View directory record Official record
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 31, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

NCT06168812
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Glipizide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCT01348100
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 31, 2026, 2:44 AM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 31, 2026, 2:44 AM EDT
Recruiting Phase 4 Interventional

Injectable Buprenorphine in Prison: A Preference Trial

NCT06880718
View directory record Official record
Conditions
Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
Interventions
Brixadi (Injectable Buprenorphine), Sublocade
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

NCT00996762
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

NCT02398669
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques

NCT01495442
View directory record Official record
Conditions
Adult Healthy Volunteers
Interventions
modified Handihaler DPI, standard Handihaler DPI
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 31, 2026, 2:44 AM EDT
Recruiting Early Phase 1 Interventional

Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain

NCT07260656
View directory record Official record
Conditions
Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions
Capsaicin Palmitate, Placebo
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

NCT00551031
View directory record Official record
Conditions
Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
29
States / cities
Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 31, 2026, 2:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

NCT06129539
View directory record Official record
Conditions
Central Precocious Puberty
Interventions
Debio 4326
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
5 Years to 8 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 31, 2026, 2:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 31, 2026, 2:44 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

NCT00865566
View directory record Official record
Conditions
HIV Infections
Interventions
DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 31, 2026, 2:44 AM EDT